Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
105 hedge funds and large institutions have $1.33B invested in Verona Pharma in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 11 closing their positions.
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
11% more funds holding
Funds holding: 95 → 105 (+10)
9% more capital invested
Capital invested by funds: $1.22B → $1.33B (+$111M)
0.33% more ownership
Funds ownership: 9.56% → 9.89% (+0.33%)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
65% less call options, than puts
Call options by funds: $3.32M | Put options by funds: $9.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$54.2M |
| 2 |
PA
Perceptive Advisors
New York
|
+$35.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$27.1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.6M |
| 5 |
Jennison Associates
New York
|
+$7.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$58.6M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$26.5M |
| 3 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$10.4M |
| 4 |
O
OrbiMed
New York
|
-$10.3M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$10.2M |
VRNA Hedge Fund Activity: Q2 2023 in Review
105 institutional investors reported a position in Verona Pharma (VRNA) for Q2 2023, worth a combined $1.33B — up 9.1% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VRNA positions and 11 closed out — a net gain of 10 holders — while 30 added to existing stakes and 32 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $54.2M. The largest seller was Fairmount Funds Management, cutting an estimated $58.6M.
- 105 institutional investors held Verona Pharma (VRNA) as of Q2 2023, up from 95 in Q1 2023.
- Funds reported $1.33B of Verona Pharma stock for Q2 2023, up 9.1% quarter-over-quarter.
- 21 funds opened new Verona Pharma positions in Q2 2023 and 11 closed out, a net change of +10 holders.
- The largest Verona Pharma buyer in Q2 2023 was Fidelity Investments, an estimated $54.2M added.
- The largest Verona Pharma seller in Q2 2023 was Fairmount Funds Management, an estimated $58.6M sold.
Based on aggregated 13F filings for Q2 2023.